Modification of signaling pathways of canine Th17 lymphocytes subset to improve Adoptive cellular immunotherapy for humans (Q84267)
Jump to navigation
Jump to search
Project Q84267 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Modification of signaling pathways of canine Th17 lymphocytes subset to improve Adoptive cellular immunotherapy for humans |
Project Q84267 in Poland |
Statements
1,999,750.0 zloty
0 references
1,999,750.0 zloty
0 references
100.0 percent
0 references
1 November 2017
0 references
31 October 2020
0 references
SZKOŁA GŁÓWNA GOSPODARSTWA WIEJSKIEGO W WARSZAWIE
0 references
Adoptive cell transfer (ACT) immunotherapy is considered the most promising treatment of cancer; however it is still limited by the use of short-lived and exhausted T cells. Recently, IL-17 producing CD4+ T lymphocytes (Th17 cells) have been shown to be superior in eradication of melanoma in mouse compared to Th1 cells. We propose to determine the expanding ex vivo protocol of Th17 cells from domestic dog in order to support comparative oncology research and improve the ACT-based immunotherapy for humans. We hypothesized that pharmacological manipulation of signaling pathways of canine Th17 cells will enhance their antitumor activity and increase the efficacy of tumor immunotherapy. We plan to evaluate the results on the tumor infiltrating lymphocytes from melanoma-bearing dogs (patients of Veterinary Clinic). The outcomes of the project will provide the rationale for designing next-generation clinical trials for human cancer patients and facilitate development of cell-based drugs. (Polish)
0 references
Adoptive cell transfer (ACT) immunotherapy is considered the most promising treatment of cancer; however it is still limited by the use of short-lived and exhausted T cells. Recently, IL-17 producing CD4+ T lymphocytes (Th17 cells) have been shown to be superior in eradication of melanoma in mouse compared to Th1 cells. We propose to determine the expanding ex vivo protocol of Th17 cells from domestic dog in order to support comparative oncology research and improve the ACT-based immunotherapy for humans. We hypothesised that pharmacological manipulation of signaling pathways of canine Th17 cells will enhance their antitumor activity and increase the efficacy of tumor immunotherapy. We plan to evaluate the results on the tumor infiltrating lymphocytes from melanoma-bearing dogs (patients of Veterinary Clinic). The outcomes of the project will provide the rationale for designing next-generation clinical trials for human cancer patients and facilitate development of cell-based drugs. (English)
14 October 2020
0 references
L’immunothérapie par transfert de cellules adoptives (ACT) est considérée comme le traitement le plus prometteur du cancer; cependant, il est encore limité par l’utilisation de cellules T de courte durée et épuisées. Récemment, l’IL-17 produisant des lymphocytes CD4+ T (cellules Th17) s’est avéré supérieur dans l’éradication du mélanome chez la souris par rapport aux cellules Th1. Nous proposons de déterminer le protocole ex vivo en expansion des cellules Th17 du chien domestique afin de soutenir la recherche comparative en oncologie et d’améliorer l’immunothérapie à base d’ACT pour les humains. Nous avons émis l’hypothèse que la manipulation pharmacologique des voies de signalisation des cellules canines Th17 améliorerait leur activité antitumorale et augmenterait l’efficacité de l’immunothérapie tumorale. Nous prévoyons d’évaluer les résultats sur les lymphocytes tumoraux infiltrés de chiens porteurs de mélanome (patients de la clinique vétérinaire). Les résultats du projet fourniront la justification de la conception d’essais cliniques de prochaine génération pour les patients atteints de cancer chez l’homme et faciliteront la mise au point de médicaments à base de cellules. (French)
30 November 2021
0 references
Identifiers
POIR.04.04.00-00-3EE9/17
0 references